|
KMID : 0982820090080010008
|
|
Journal of Lung Cancer
2009 Volume.8 No. 1 p.8 ~ p.12
|
|
|
Concurrent Chemoradiotherapy with Weekly Paclitaxel for Locally Advanced Non-small Cell Lung Cancer
|
|
Jeong Seong-Hyun
Jung Jae-Ho
Lee Hyun-Woo
Kang Seok-Yun
Ahn Mi-Sun
Choi Yong-Won
Hwang Yoon-Ho
Oh Young-Taek
Choi Jin-Hyuk
Shin Seung-Soo
Park Kwang-Joo
|
|
|
Abstract
|
|
|
Purpose: Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced non-small cell lung cancer (NSCLC). Paclitaxel is an active agent against NSCLC and it has a radiosensitizing effect. We investigated the efficacy and toxicity of weekly paclitaxel administration along with concurrent radiotherapy for treating locally advanced and locally recurrent NSCLC.
Materials and Methods: Twenty-five previously untreated stage III or locally recurrent NSCLC patients received weekly paclitaxel (60 mg/m2) and concurrent radiotherapy. Chemotherapy was given on days 1, 8, 15 and 22. Concurrent radiotherapy at 1.5 Gy was given twice a day to a total dose of 54 Gy in 3.5 weeks. After the completion of CCRT, consolidation chemotherapy was delivered if possible.
Results: The overall response rate was 72% with one complete response and 17 partial responses. The median overall survival was 16 months with a 2 year survival rate and a 5 year survival rate of 38% and 24%, respectively. The rate of grade ≥3 radiation pneumonitis was 16% (4 patients) and 2 patients were died from the pneumonitis. The rate of grade 3 radiation esophagitis was 12% (3 patients) and the hematologic toxicities were not significant.
Conclusion: Weekly paclitaxel with concurrent radiotherapy is effective for treating locally advanced and locally recurrent NSCLC, but radiation pneumonitis is the major toxicity and this is potentially fatal.
|
|
|
KEYWORD
|
|
|
Non-small cell lung carcinoma, Concurrent chemoradiotherapy, Paclitaxel
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|